1377.9000 -2.10 (-0.15%)
NSE Nov 16, 2026 15:51 PM
Volume: 975.0K
 

1377.90
-0.15%
Emkay
Dr Reddy’s’ Form 20-F disclosures indicate that gRevlimid sales in FY26 were closer to our base-case estimate (~$300mn). However, assuming muted growth in the company’s base oncology portfolio since FY22, gRevlimid contribution would have been higher by ~$100mn in FY26 vs our base case.
Dr. Reddy's Laborato.. has an average target of 1335.44 from 9 brokers.
More from Dr. Reddy's Laboratories Ltd.
Recommended